The Efficacy And Safety Of Iguratimod In The Treatment Of Primary Sjogren’s Syndrome Using Meta-analysis

Objective: To make a study about the efficacy and safety of the combination of Iguratimod on the basis of traditional treatment for primary Sjogren’s syndrome using Meta-analysis.Methods: The published literatures related to treatment of primary Sjogren’s syndrome with Iguratimod were searched by computer retrieval from CNKI,Wanfang,VIP,CBM,Pubmed,Embase,The Cochrane Library.The scope of search was to January 2021.Eligible literatures were included and relevant outcome measures were extracted,and relevant data were processed by software Rev Man 5.4 for Meta-analysis.Results: Eight RCTs were finally included,adding up to 654 patients with primary Sjogren’s syndrome.The Meta-analysis indicated that,there was obvious difference in the improvement of ESSDAI between the IGU group and the control group,MD=-2.18,95%CI(-2.72,-1.63),P<0.00001,and the reduction in ESSDAI score in the IGU group was better;there was obvious difference in the total effective rate between the two groups,RR=1.39,95%CI(1.19,1.62),P<0.0001,and it was higher in the IGU group.There were no obvious differences in the incidence of total side effects [RR=1.09,95%CI(0.71,1.66),P=0.70],the incidence of gastrointestinal adverse reactions [RR=1.28,95%CI(0.71,2.31),P=0.42],the incidence of abnormal liver functions [RR=1.12,95%CI(0.45,2.77),P=0.81],and the incidence of rash or pruritus [RR=1.09,95% CI(0.51,2.32),P=0.83] between the IGU group and the control group.Conclusion: The rational combination therapy with Iguratimod is superior to the traditional treatment regimens in the treatment of primary Sjogren’s syndrome.It can reduce the disease activity and show no statistical difference in the occurrence of side effects compared to the traditional treatment,with comparable safety.However,this study has some limitations,p SS is a chronic disease.In the future,more high-quality research evidence is still needed to verify its efficacy.